BioCentury
ARTICLE | Finance

Activation on cue

MDB re-ups with Cue as immunotherapy play emerges from stealth

January 27, 2017 11:50 PM UTC

Cue Biopharma Inc. emerged from stealth mode last week with a financing led by MDB Capital Group that will enable the cancer play to reach the clinic with its lead therapy, which could trigger a targeted T cell response while avoiding the toxicities associated with CAR T therapies.

The $16.4 million venture round also saw participation from undisclosed high net worth individuals...

BCIQ Company Profiles

Cue Biopharma Inc.